Smallpox drug, brincidofovir, shows promising results in study

Durham, NC based biopharmaceutical company, Chimerix announced yesterday that its investigational antiviral brincidofovir showed a survival benefit in a pivotal study of an animal model for smallpox. Chimerix is developing brincidofovir as a medical countermeasure against smallpox, for which there is no antiviral agent currently approved. Brincidofovir has demonstrated broad-spectrum in vitro activity across five families of ["]